Correspondence
A Community Cluster of Oseltamivir-Resistant Cases of 2009 H1N1 Influenza
N Engl J Med 2010; 362:86-87January 7, 2010
- Article
To the Editor:
Oseltamivir-resistant infection with the 2009 pandemic influenza A (H1N1) virus has so far been described only rarely and is conferred by the H275Y substitution in the neuraminidase enzyme.1 Only 3 of the 32 patients with oseltamivir-resistant infection reported on as of this writing were not receiving oseltamivir when the resistant viruses were detected, and ongoing community transmission has not yet been shown.1 However, the emergence of oseltamivir-resistant 2009 H1N1 influenza remains a grave concern, since widespread oseltamivir resistance has been observed in seasonal H1N1. This resistance was unrelated to selective drug pressure, and the H275Y substitution did not appear to reduce transmissibility or severity.2,3 We report on a cluster of seven cases of oseltamivir-resistant 2009 H1N1 infection in Vietnam.
In July 2009, during a 42-hour journey, 10 students socialized together in the same train carriage. None of the students knew each other before the journey, none had contact with a person with suspected influenza in the week before the trip, none were symptomatic during the journey, and none were previously or currently receiving oseltamivir. Fever developed in four of the students within 12 hours after arrival and in two more students within 48 hours after arrival (Fig. 1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). An additional case was identified in a traveler in a different carriage (Patient G). Nasal swabs, throat swabs, or both from all seven persons were positive for 2009 H1N1 RNA when tested with reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays, and viruses were successfully cultured from specimens obtained from three of the persons. The H275Y substitution was detected retrospectively in diagnostic specimens obtained from all seven subjects before any oseltamivir treatment. The concentrations of oseltamivir carboxylate required for a 50% inhibition of neuraminidase activity of the isolated viruses in a fluorometric neuraminidase-inhibition assay were 323.6, 429.5, and 889.2 nM; these concentrations confirmed resistance4 (see the Supplementary Appendix).
Six patients were admitted to a hospital for isolation, one patient was isolated at home, and all were treated with oseltamivir phosphate at a dose of 75 mg twice daily (Fig. 1 in the Supplementary Appendix), since resistance testing had not yet been performed. All patients recovered uneventfully, although one patient (Patient F), with the highest 50% inhibitory concentration, continued to test positive on RT-PCR until day 9, despite receiving oseltamivir from the day of the onset of illness (Fig. 1 in the Supplementary Appendix). An extensive public health investigation did not identify additional patients or the index patient.
In this cluster, infection developed in at least 6 of the 10 people who were probably exposed to the index patient; this shows that resistant 2009 H1N1 viruses are transmissible and can replicate and cause illness in healthy people in the absence of selective drug pressure. Ongoing transmission from the cluster was not detected, but the tracing of all contacts was not possible, so ongoing transmission cannot be ruled out. However, only three other resistant cases have been detected in Vietnam as of this writing, and all were due to selection of resistant viruses during treatment rather than person-to-person transmission. Although data are limited, it is likely that the detected levels of oseltamivir resistance are clinically relevant.5 The loss of oseltamivir as a treatment option for severe 2009 H1N1 infection could have profound consequences. To minimize this risk, the use of oseltamivir should be restricted to prophylaxis and treatment in high-risk persons or the treatment of people with severe or deteriorating illness, antiviral stockpiles should be diversified, and optimal dosages and combination therapies should be urgently studied. Close monitoring and reporting of resistance to neuraminidase inhibitors are essential.
Le Quynh Mai, M.D., Ph.D.
National Institute of Hygiene and Epidemiology, Hanoi, VietnamHeiman F.L. Wertheim, M.D., Ph.D.
Oxford University Clinical Research Unit, Hanoi, VietnamTran Nhu Duong, M.D., Ph.D.
National Institute of Hygiene and Epidemiology, Hanoi, VietnamH. Rogier van Doorn, M.D., Ph.D.
Oxford University Clinical Research Unit, Ho Chi Minh City, VietnamNguyen Tran Hien, M.D., Ph.D.
National Institute of Hygiene and Epidemiology, Hanoi, VietnamPeter Horby, M.B., B.S., F.F.P.H.
Oxford University Clinical Research Unit, Hanoi, Vietnam
peter.horby@gmail. com for the Vietnam H1N1 Investigation Team
Supported by grants from the Wellcome Trust United Kingdom (081613/Z/06/Z and 077078/Z/05/Z, to Drs. Wertheim, van Doorn, and Horby) and the South East Asia Infectious Disease Clinical Research Network (N01-A0-50042, to Drs. Wertheim, van Doorn, and Horby).
Financial and other disclosures provided by the authors are available with the full text of this letter at NEJM.org.
This letter (10.1056/NEJMc0910448) was published on December 9, 2009, at NEJM.org.
5 References1
Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009. Wkly Epidemiol Rec 2009;84:453-459
Medline2
Moscona A . Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009;360:953-956
Full Text | Web of Science | Medline3
Cianco B ,Meerhoff T ,Kramarz P , et al. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiological and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. Euro Surveill 2009;14:pii=19412-pii=19412
Medline4
Wetherall NT ,Trivedi T ,Zeller J , et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the Neuraminidase Inhibitor Susceptibility Network. J Clin Microbiol 2003;41:742-750
CrossRef | Web of Science | Medline5
Wattanagoon Y ,Stepniewska K ,Lindegardh N , et al. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother 2009;53:945-952
CrossRef | Web of Science | Medline
- Citing Articles (21)
Citing Articles
1
Afroditi Kourti, Grecory Spanakos, Leda Politi, Anastasia Stavropoulou, Nicholas Spanakis, Athanassios Tsakris. (2012) Oseltamivir-resistant influenza A(H1N1) 2009 virus in Greece during the post-pandemic 2010–2011 season. International Journal of Antimicrobial Agents
CrossRef2
A. T. Pavia. (2012) What did we learn from the Emergency Use Authorization of peramivir in 2009?. Clinical Infectious Diseases
CrossRef3
Aeron C Hurt, Tawee Chotpitayasunondh, Nancy J Cox, Rod Daniels, Alicia M Fry, Larisa V Gubareva, Frederick G Hayden, David S Hui, Olav Hungnes, Angie Lackenby, Wilina Lim, Adam Meijer, Charles Penn, Masato Tashiro, Timothy M Uyeki, Maria Zambon. (2012) Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. The Lancet Infectious Diseases 12:3, 240-248
CrossRef4
Shivanjali Shankaran, Gonzalo M. L. Bearman. (2012) Influenza Virus Resistance to Neuraminidase Inhibitors: Implications for Treatment. Current Infectious Disease Reports
CrossRef5
Tarangsri Nivitchanyong, Suganya Yongkiettrakul, Jarin Kramyu, Supitcha Pannengpetch, Nanchaya Wanasen. (2011) Enhanced expression of secretable influenza virus neuraminidase in suspension mammalian cells by influenza virus nonstructural protein 1. Journal of Virological Methods 178:1-2, 44-51
CrossRef6
Tatiana Baranovich, Robert G Webster, Elena A Govorkova. (2011) Fitness of neuraminidase inhibitor-resistant influenza A viruses. Current Opinion in Virology 1:6, 574-581
CrossRef7
Sunchai Payungporn, Wittaya Poomipak, Jarika Makkoch, Pornpimol Rianthavorn, Apiradee Theamboonlers, Yong Poovorawan. (2011) Detection of oseltamivir sensitive/resistant strains of pandemic influenza A virus (H1N1) from patients admitted to hospitals in Thailand. Journal of Virological Methods 177:2, 133-139
CrossRef8
N. Adriaenssens, S. Coenen, A. C. M. Kroes, A. Versporten, V. Vankerckhoven, A. Muller, H. S. Blix, H. Goossens, , H. Mittermayer, S. Vaerenberg, B. Markova, A. Andrasevic, A. Kontemeniotis, J. Vlcek, N. Frimodt-Moller, L. Rootslane, J. Vuopio-Varkila, P. Cavalie, W. Kern, H. Giamarellou, G. Ternak, H. Briem, R. Cunney, R. Raz, P. Folino, U. Dumpis, R. Valinteliene, M. Bruch, M. Borg, S. Natsch, H. S. Blix, W. Hryniewicz, M. Ribeirinho, A. Baicus, S. Ratchina, V. Foltan, M. Cizman, J. Campos, G. Skoog, G. Zanetti, S. Unal, P. Davey. (2011) European Surveillance of Antimicrobial Consumption (ESAC): systemic antiviral use in Europe. Journal of Antimicrobial Chemotherapy 66:8, 1897-1905
CrossRef9
Gabriele Neumann, Yoshihiro Kawaoka. (2011) The first influenza pandemic of the new millennium. Influenza and Other Respiratory Viruses 5:3, 157-166
CrossRef10
Sallene Wong, Kanti Pabbaraju, Anita Wong, Kevin Fonseca, Steven J. Drews. (2011) Development of a real-time RT-PCR assay for detection of resistance to oseltamivir in influenza A pandemic (H1N1) 2009 virus using single nucleotide polymorphism probes. Journal of Virological Methods 173:2, 259-265
CrossRef11
Yi-Mo Deng, Natalie Caldwell, Aeron Hurt, Tim Shaw, Anne Kelso, Glenys Chidlow, Simon Williams, David Smith, Ian Barr. (2011) A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses. Antiviral Research 90:1, 87-91
CrossRef12
Susan Bennett, Rory N. Gunson, Alasdair MacLean, Rhona Miller, William F. Carman. (2011) The validation of a real-time RT-PCR assay which detects influenza A and types simultaneously for influenza A H1N1 (2009) and oseltamivir-resistant (H275Y) influenza A H1N1 (2009). Journal of Virological Methods 171:1, 86-90
CrossRef13
Ashleigh Tuite, Beate Sander, Nick Pizzi, S.M. Moghadas, Amy Greer, S. Driedger, Fred Brauer, Chris Bauch, Julien Arino, P. van den Driessche, James Watmough, Jianhong Wu, Ping Yan. (2011) Pandemic influenza: Modelling and public health perspectives. Mathematical Biosciences and Engineering 8:1, 1-20
CrossRef14
Nao Nukiwa, Akira Suzuki, Yuki Furuse, Kozue Shimabukuro, Takashi Odagiri, Irona Khandaker, Hitoshi Oshitani. (2010) Simplified screening method for detecting oseltamivir resistant pandemic influenza A (H1N1) 2009 virus by a RT-PCR/restriction fragment length polymorphism assay. Journal of Virological Methods 170:1-2, 165-168
CrossRef15
Ji-Rong Yang, Yuan-Pin Huang, Yu-Cheng Lin, Chun-Hui Su, Chuan-Yi Kuo, Li-Ching Hsu, Ho-Sheng Wu, Ming-Tsan Liu. (2010) Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan. Antiviral Research 88:3, 256-262
CrossRef16
P. A. Chan, N. T. Connell, A. M. Gabonay, B. Westley, J. M. Larkin, S. P. LaRosa, K. Chapin, L. Mermel. (2010) Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient. Clinical Microbiology and Infection 16:10, 1576-1578
CrossRef17
C. Renaud, J. Kuypers, L. Corey. (2010) Diagnostic accuracy of an allele-specific reverse transcriptase-PCR assay targeting the H275Y oseltamivir resistant mutation in 2009 pandemic influenza A/H1N1 virus. Journal of Clinical Virology 49:1, 21-25
CrossRef18
Bin Wang, Dominic E. Dwyer, Christopher C. Blyth, Maly Soedjono, Haijing Shi, Alison Kesson, Mala Ratnamohan, Ken McPhie, Anthony L. Cunningham, Nitin K. Saksena. (2010) Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antiviral Research 87:1, 16-21
CrossRef19
Brianne A. Couturier, Jeffrey M. Bender, Monica A. Schwarz, Andrew T. Pavia, Kimberly E. Hanson, Rosemary C. She. (2010) Oseltamivir-resistant influenza A 2009 H1N1 virus in immunocompromised patients. Influenza and Other Respiratory Viruses 4:4, 199-204
CrossRef20
Meier, Markus H., . (2010) More on Integrated Delivery Systems. New England Journal of Medicine 362:13, 1247-1248
Full Text21
M.A. Bürkle, L. Frey, B. Zwißler. (2010) Neue Influenza-A/H1N1-2009-Virus-Pandemie. Der Anaesthesist 59:1, 11-22
CrossRef
